alemtuzumab + busulfan + cyclophosphamide + fludarabine + thiotepa

This is a combination conditioning regimen used primarily in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), especially for patients with hematologic malignancies such as acute myeloid leukemia (AML). The regimen combines five agents: - Alemtuzumab, a monoclonal antibody targeting CD52, providing immunosuppression and reducing graft-versus-host disease. - Busulfan, an alkylating agent that ablates bone marrow cells. - Cyclophosphamide, another alkylating agent with both cytotoxic and immunosuppressive effects. - Fludarabine, a purine analog that inhibits DNA synthesis and provides additional immunosuppression. - Thiotepa, an alkylating agent known for its ability to cross the blood-brain barrier and provide myeloablative effects. The combination is designed to maximize disease eradication while facilitating engraftment of donor cells and minimizing relapse risk. This multi-agent approach is typically reserved for high-risk or refractory cases or when specific transplant protocols require enhanced immunoablation. Each component has a distinct mechanism of action contributing to overall efficacy in conditioning prior to HSCT[1][2][4].

Brand names

CampathFludaraBusulfexTepadina

Other names

Myeloablative Conditioning Regimen-Randy Windreich-acute myeloid leukemia-myelodysplastic syndromesMAC regimenWindreich MAC regimen